Hospital Vall d’Hebron
- Address
- Passeig De La Vall D'Hebron 119-129, 08035 Barcelona, Spain
Cardiovascular Diseases at Hospital Vall d’Hebron
Research here focuses on pulmonary arterial hypertension, a serious condition affecting the blood vessels in the lungs. The trials are designed to explore whether targeted supportive treatment can improve symptoms, functional capacity, and risk status while helping prevent clinical worsening.
- Studying pulmonary arterial hypertension in patients with idiopathic, hereditary, drug- and toxin-induced, and connective tissue disease-associated forms
- Evaluating vitamin D supplementation as a potential way to improve clinical outcomes and reduce worsening of disease
This work reflects a strong interest in better managing cardiopulmonary complications through more effective supportive care and outcome monitoring.
Immune System Diseases
The Lupus Unit at Vall d’Hebron Institut de Recerca is conducting research in systemic lupus erythematosus, especially severe and treatment-resistant cases. These studies aim to assess new therapeutic options for improving disease control and safety in people with difficult-to-manage autoimmune disease.
- Investigating severe, refractory systemic lupus erythematosus in patients who need better treatment options
- Testing a new cell-based therapy to evaluate early signs of benefit and tolerability
The research highlights ongoing efforts to advance care for complex autoimmune diseases by finding approaches that may offer meaningful improvement where standard treatments are not enough.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 40 therapeutic areas and 15 of 1 562 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 1 508 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 433 by active trials.
- 1AstraZeneca AB58active
lock +432 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC128trials
lock +271 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Vall d’Hebron
lock Showing 1 of 2 347 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | Bayer AG, Bayer Consumer Care AG | Phase II | Not Recruiting | Jun 2016 | Sep 2025 |
IMP list
lock Showing 1 of 1 562 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 184 | Unknown | 2015-11-06 | 2026-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.